| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 800 | 2018 |
| REV7 counteracts DNA double-strand break resection and affects PARP inhibition G Xu, JR Chapman, I Brandsma, J Yuan, M Mistrik, P Bouwman, ... Nature 521 (7553), 541-544, 2015 | 581 | 2015 |
| Subunit composition of VRAC channels determines substrate specificity and cellular resistance to P t‐based anti‐cancer drugs R Planells‐Cases, D Lutter, C Guyader, NM Gerhards, F Ullrich, DA Elger, ... The EMBO journal 34 (24), 2993-3008, 2015 | 235 | 2015 |
| Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ... Science 366 (6466), 714-723, 2019 | 224 | 2019 |
| CopywriteR: DNA copy number detection from off-target sequence data T Kuilman, A Velds, K Kemper, M Ranzani, L Bombardelli, M Hoogstraat, ... Genome biology 16, 1-15, 2015 | 216 | 2015 |
| HELB is a feedback inhibitor of DNA end resection J Tkáč, G Xu, H Adhikary, JTF Young, D Gallo, C Escribano-Díaz, ... Molecular cell 61 (3), 405-418, 2016 | 158 | 2016 |
| ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer G Xu, S Chhangawala, E Cocco, P Razavi, Y Cai, JE Otto, L Ferrando, ... Nature genetics 52 (2), 198-207, 2020 | 152 | 2020 |
| BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance JE Jaspers, W Sol, A Kersbergen, A Schlicker, C Guyader, G Xu, ... Cancer research 75 (4), 732-741, 2015 | 66 | 2015 |
| PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of ER-dependent gene expression E Toska, P Castel, S Chhangawala, A Arruabarrena-Aristorena, C Chan, ... Cell reports 27 (1), 294-306. e5, 2019 | 57 | 2019 |
| Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance M Warmoes, JE Jaspers, G Xu, BK Sampadi, TV Pham, JC Knol, ... Molecular & Cellular Proteomics 12 (5), 1319-1334, 2013 | 33 | 2013 |
| Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells G Xu, C Zhang, J Zhang Molecular Medicine Reports 2 (5), 819-824, 2009 | 31 | 2009 |
| Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors Y Cai, G Xu, F Wu, F Michelini, C Chan, X Qu, P Selenica, E Ladewig, ... Cancer research 81 (9), 2470-2480, 2021 | 23 | 2021 |
| Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex W Xie, S Wang, J Wang, MJ de la Cruz, G Xu, M Scaltriti, DJ Patel Proceedings of the National Academy of Sciences 118 (8), e2024512118, 2021 | 22 | 2021 |
| Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers N Mao, Z Zhang, YS Lee, D Choi, AA Rivera, D Li, C Lee, S Haywood, ... Nature Communications 12 (1), 5053, 2021 | 16 | 2021 |
| Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations J Gómez Tejeda Zañudo, P Mao, C Alcon, K Kowalski, GN Johnson, G Xu, ... Cancer research 81 (17), 4603-4617, 2021 | 12 | 2021 |
| PARP inhibitor resistance—what is beyond BRCA1 or BRCA2 restoration? G Xu, J Jonkers, S Rottenberg PARP Inhibitors for Cancer Therapy, 453-471, 2015 | 3 | 2015 |
| Abstract NG16: Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ... Cancer Research 80 (16_Supplement), NG16-NG16, 2020 | 1 | 2020 |
| Cell-line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations JGT Zañudo, P Mao, C Alcon, KJ Kowalski, GN Johnson, G Xu, J Baselga, ... bioRxiv, 0 | 1 | |
| NR2F2 mediates cell growth and endocrine resistance in NF1 loss, ER+ breast cancer Y Cai, P Zhao, F Wu, H Shao, P Razavi, G Xu, M Scaltriti, ... Cancer Research 82 (12_Supplement), 1778-1778, 2022 | | 2022 |
| Abstract NG05: Epigenetic mechanisms of endocrine therapy response in breast cancer E Toska, G Xu, A Arruabarrena-Aristorena, M Scaltriti Cancer Research 81 (13_Supplement), NG05-NG05, 2021 | | 2021 |
Jos JonkersSenior Group Leader, Division of Molecular Pathology, Netherlands Cancer Institute, Oncode InstituteVerified email at nki.nl
